Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.37 USD | -1.79% | -2.42% | -10.92% |
10/05 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
01/05 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.92% | 622.49Cr | |
+3.91% | 11TCr | |
+10.87% | 11TCr | |
-0.26% | 2.23TCr | |
-13.14% | 2.21TCr | |
-8.05% | 1.87TCr | |
-38.36% | 1.76TCr | |
-10.66% | 1.69TCr | |
+3.75% | 1.38TCr | |
+36.70% | 1.25TCr |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Morgan Stanley Adjusts Price Target on Exelixis to $22 From $21, Maintains Equal-Weight Rating